Antiretroviral therapy in people with HIV and end-stage kidney disease
No Thumbnail Available
Authors
Spencer, Matthew
Pieri, Christopher
Hamzah, Lisa
Popoola, Joyce
Shah, Sapna
Jones, Rachael
Levy, Jeremy
Murphy, Maurice
Booth, John
Post, Frank A.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
OBJECTIVE: To summarize antiretroviral therapy (ART) use in the setting of end-stage kidney disease (ESKD). DESIGN: Cross-sectional analysis. METHODS: Descriptive analysis of ART regimens and dose of nucleoside/nucleotide reverse-transcriptase inhibitors (NRTI) in people with HIV and ESKD [dialysis, kidney transplantation, or estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m 2 ] receiving HIV and renal care at five London centres. Exposures of interest were use of dual/unboosted ART regimens and higher than recommended doses of renally cleared NRTI. RESULTS: A total of 157 participants were included (median age 55 years, 66% men, 84% black ethnicity, median CD4 + cell count 382 cells/μl, 99% HIV RNA <200 copies/ml). Fifty-eight (37%) were on dual/unboosted ART regimens, mainly dolutegravir/lamivudine. Participants on dual/unboosted ART had similar rates of HIV suppression as those on triple ART. Two participants currently virologically controlled on triple-ART had previously failed to suppress on dual/unboosted ART [dolutegravir/rilpivirine and dolutegravir/lamivudine (50 mg)]. Lamivudine doses were higher than recommended in 75 (77%) and lower than recommended in 8 (8%) participants. Full-dose lamivudine (300 mg daily) was used by 24 (32%) participants with eGFR less than 30 ml/min/1.73m 2 . None of those currently on reduced-dose lamivudine had required dose reductions for previous toxicity concerns. CONCLUSION: Dual/unboosted ART regimens, such as dolutegravir/lamivudine, provide robust viral efficacy in the setting of ESKD, and higher than recommended, including full-dose, lamivudine was well tolerated. The dolutegravir/lamivudine (300 mg) fixed-dose combination provides a single-tablet regimen for use across the eGFR spectrum, avoids under-exposure to lamivudine, and merits further evaluation in this population.
Description
Citation
Publisher
License
Journal
AIDS
Volume
39
Issue
7